Review Paper:
A Review on Metabolic
Biomarkers for Cardiac Hypertrophy
Padmanabhan Arul Mozhi and Doss V.A.
Res. J. Chem. Environ.; Vol. 29(1); 67-74;
doi: https://doi.org/10.25303/291rjce067074; (2025)
Abstract
Cardiac hypertrophy is characterized by an increase in cardiac thickness distinguished
from normal cardiac anatomy with typical elevated cardiac function. Over the last
decade, metabolomics has made tremendous progress in the scientific interpretation
of molecular disease processes. Certain clinical aspects and therapeutic efficacy
rely upon biomarkers that can also distinguish individuals with Dilated Cardiomyopathy
and Hypertrophic Cardiomyopathy.
The fluctuations in the metabolic flux of the biochemical pathway are specifically
quantified by targeted metabolomic methods. Non-targeted metabolomics invariably
tends to have more data than targeted metabolomics and it is much more quantitative
for the most part. The myriad metabolites as well as the pertinence of being a metabolic
biomarker for diagnosis and clinical targets of cardiac hypertrophy are addressed
in this current review.
